SCHEMBL9612480

SCHEMBL9612480

c1ccc2cc3c(ccc4c(-c5ccc(N(c6ccc(-c7cccc8c7ccc7cc9ccccc9cc78)cc6)c6ccc(-c7cccc8c7ccc7cc9ccccc9cc78)cc6)cc5)cccc43)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 4/20 0.42
HIF1A Q16665 2/20 0.42
CYP1B1 Q16678 1/20 0.42
CYP1A2 P05177 3/20 0.40
ERBB2 P04626 1/20 0.40
FYN P06241 1/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.40
AHR P35869 1/20 0.40
HPGD P15428 4/20 0.38
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
HPRT1 P00492 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995209 0.90 ALDH1A1 (0.52) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL25089134 0.87 HPRT1 (0.45) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL10246863 0.87 GSTP1 (0.37) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL25089143 0.87 HPRT1 (0.45) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL5552277 0.87 ALDH1A1 (0.38) ALDH1A1HSD17B10HIF1ACYP1A2HPGD
SCHEMBL31534001 0.87 ALDH1A1 (0.38) ALDH1A1HSD17B10HIF1ACYP1A2HPGD
SCHEMBL27048773 0.86 HPRT1 (0.52) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL25088893 0.86 CA12 (0.43) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL31290733 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2
SCHEMBL25088715 0.86 CA12 (0.44) ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
EP-2148909-B1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-05-30 EP disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES KCNT1, KCNC1, TMEM109 ALDH1A1 26/4885HSD17B10 936/4885HIF1A 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.